In 1992, recombinant human interleukin-2 (rhIL-2), produced by genetic engineering technology, was approved for the treatment of kidney cancer whereas it was approved for the treatment of metastatic melanoma in 1998 (46). This evidence concerns the gene IL2 and metastatic melanoma.